While there have been many sober warnings about AI and recursive self-improvement, Arianna Huffington argues that it is a ...
Copyright: © 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Unequal access to AI is ...
Recursion (NASDAQ: RXRX) and Exscientia PLC (NASDAQ: EXAI) have announced that their shareholders have overwhelmingly approved the proposed combination between the two companies. The transaction is ...
Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
A London-based AI startup set up just months ago, which believes it’s pursuing the fastest path to surpassing human intelligence, has today come out of stealth, having raised over $650m at a $4.65bn ...
The computational manipulation of polynomials is a foundational element across pure and applied mathematics, computer algebra, cryptography and scientific computing. Central tasks include ...
Taylor, who joined Recursion through the merger with Exscientia about 18 months ago, described how the combined company aims to address multiple points of failure in drug development. He said ...
Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
Recursion Pharmaceuticals utilizes a proprietary operating system (OS) and an AI-powered algorithm that continuously runs virtual experiments, testing compounds against a library of human genes to ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results